Aiwu He, MD
Enriched profileProfessor of Medicine, Director of Hepatobiliary Cancers, Division of Hematology and Oncology, Columbia University Medical Center · Columbia University in the City of New York
Aiwu He is Professor of Medicine, Director of Hepatobiliary Cancers, Division of Hematology and Oncology, Columbia University Medical Center at Columbia University in the City of New York. OpenAlex indexes 360 publications with 12,315 citations (h-index 44); ClinicalTrials.gov lists 9 registered studies with this person as an investigator.
Data verified 19 Oct 2026
Overview
Updated 19 Oct 2026
Aiwu He, MD, PHD, is Professor of Medicine, Director of Hepatobiliary Cancers, Division of Hematology and Oncology, Columbia University Medical Center at Columbia University in the City of New York. The public record shows 360 publications with 12,315 citations (h-index 44), centered on Hepatocellular Carcinoma Treatment and Prognosis, Cancer Immunotherapy and Biomarkers, Colorectal Cancer Treatments and Studies. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 22 companies.
- Most recent indexed publication: 2026 · Hepatology communications
- Top research focus: Hepatocellular Carcinoma Treatment and Prognosis
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 22 companies
Generated from the cited public record · current as of 19 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 10 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 107.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Public positions
sourced statements on record- Director of Hepatobiliary Cancer
Department of Medicine, Division of Hematology and Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 19 Oct 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors
Sponsor: OncoC4, Inc.
InvestigatorPhase 1Not, yet, recruitingNCT07408258 - Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma
Sponsor: Georgetown University
- TheraSphere With Durvalumab and Tremelimumab for HCC
Sponsor: Boston Scientific Corporation
Industry payments
Updated 19 Oct 2026
22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year202512 payments$33,338openpaymentsdata.cms.gov ↗
- Eisai Inc.Program year202521 payments$25,630openpaymentsdata.cms.gov ↗
- AstraZeneca Pharmaceuticals LPProgram year20259 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
37.1%Opioid Agonist37.1%Oxycodone Hcl68%Morphine Sulfate Er32%Part D<11 patientsMetabolism & gastrointestinal
22.8%Proton pump inhibitor10.1%Pantoprazole Sodium100%Part D≥13 patientsSerotonin-3 Receptor Antagonist6.8%Ondansetron Odt100%Part D≥12 patients+ 1 more class in this area
Genitourinary & hormones
12.2%Progestin7.6%Megestrol Acetate100%Part D<11 patientsalpha-Adrenergic Blocker4.6%Tamsulosin Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 19 Oct 2026
134 congress contributions (2006–2026) across AACR, ASCO, ASH, ASTRO, ESMO per OpenAlex. The most recent:
- BXCL701 plus pembrolizumab in second-line advanced pancreatic ductal adenocarcinoma: Final outcomes of the EXPEL PANC trial.
ASCO Annual Meeting
ASCO2026Co-author - CheckMate-9DW 4-year follow-up: Overall survival by depth of response and outcomes in long-term survivors.
ASCO Annual Meeting
ASCO2026Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 19 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Predictors of overall survival in advanced biliary tract cancer in the phase 3 TOPAZ-1 study.
Hepatology communications
Article2026 - A Phase I Dose-Escalation Study of Polyphenon E in Liver Cirrhosis: Evaluation of Safety and Effect on Liver γ-OHPdG Levels.
Cancer prevention research (Philadelphia, Pa.)
Clinical Trial2025 - Detecting Early Recurrence With Circulating Tumor DNA in Stage I-III Biliary Tract Cancer After Curative Resection.
JCO precision oncology
Article2025 - TKIs beyond immunotherapy predict improved survival in advanced HCC.
Journal of cancer research and clinical oncology
Article2023
Most-cited works
by citation count (OpenAlex)- 01
- 02Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract CancerArticle1,209 citations2022
- 03
- 04
- 05The Role of Angiogenesis in Hepatocellular CarcinomaArticle538 citations2018
Network
Updated 19 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 19 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Mentions by others
where others cite or feature them- Other
cancer.columbia.edu/news/aiwu-ruth-he-md-phd-bridging-lab-and-clinic-transform-liver-cancer-care
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancer.columbia.edu ↗ - Other
onclive.com/authors/aiwu-ruth-he-md-phd
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 19 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.columbia.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.columbia.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doctors.columbia.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗
Secondary affiliations
appointments beyond the home institution- Director of Liver Transplant Oncology
Center for Liver Disease and Transplantation, Columbia University Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗ - Associate Professor
Georgetown University (past)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗
Media & interviews
press, podcasts and appearances- Podcast interview
Rare Disease Advisor, Episode 54, November 2022, discussing TOPAZ-1 clinical trial
2022verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →feeds.audioboom.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH